On September 22, 2022, Sangamo Therapeutics, Inc. and Pfizer Inc. announced that the registrational Phase 3 AFFINE clinical trial evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of moderately severe to severe hemophilia A that Sangamo and Pfizer are jointly developing pursuant to a collaboration agreement, has re-opened recruitment. Sangamo and Pfizer expect trial sites to resume enrollment in September 2022, with dosing expected to resume in October 2022. All trial sites are anticipated to be active by the end of 2022, and a pivotal readout is expected in the first half of 2024.
Market Closed -
Other stock markets
|
After market 05:38:41 pm | |||
28.16 USD | +1.26% | 28.15 | -0.04% |
02:14pm | Pfizer: Citi analyst appointed Chief Strategy Officer | CF |
01:45pm | Pfizer Names Andrew Baum as Chief Strategy, Innovation Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.19% | 157B | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Sangamo Therapeutics, Inc. and Pfizer Inc. Provides Update on Giroctocogene Fitelparvovec (Hemophilia A)